Endocrine Abstracts

Introduction: Deranged mitochondrial biogenesis has been linked to obesity with or without type 2 diabetes but this association has not been reported in non obese type 2 diabetes subjects. This study attempts to identify the various alterations of mitochondrial biogenesis in adipose tissue in obese and non obese type 2 diabetes subjects.Methods & Design: Since type 2 diabetes is associated with elevated serum leptin and depressed serum adiponectin le...

Introduction: Deranged Mitochondrial bioenergetics is a key feature of type 2 diabetes and obesity but its status in non-obese type 2 diabetes patients is not known. The aim of the present study was to assess the status of mitochondrial oxidative phosphorylation and ROS metabolism in subcutaneous adipose tissue isolated from 4 groups of subjects: non-obese subjects with type 2 diabetes (NOT2D), non-obese non diabetic (C), obese non-diabetic (OB) and obese type 2 diabetes subje...

Background: TQ Formula (TQ, C10H12O2), is an oral formulation, derived from the black seed (Nigella sativa, Ranunculaceae family), and has anti-oxidant, anti-angiogenic effects. TQ Formula has been shown to induce significant immune modulatory effects in a recently published Covid-19 study. Previous studies reported blackseed’s apoptotic and anti-proliferative effects of its components on multiple cancer types, including colon, breast and ovarian adenocarcinoma. Our preli...

Background: The role of surgical cytoreduction for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is considered an area of debate due to lack of prospective data. While retrospective and single institution analyses demonstrated higher survival rates associated with surgical cytoreduction, there was no comparison with systemic therapies alone in these studies. The aim of this analysis of the National Cancer Database (NCDB) was to evaluate the survival benefi...

Background: Peptide receptor radionuclide therapy (PRRT) including Lutetium177 (Lu177) has changed the treatment landscape of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who are resistant or develop resistance after initial success to PRRT, indicating that accurate predictive markers are urgently needed to identify who will benefit from PRRT. We hypothesize that expression of ATRX (Alpha Thalassemia and Mental Retardation...

Background: Somatostatin analogues (SSAs) are the standard of care first line therapy for metastatic well-differentiated neuroendocrine tumors (NETs). They are approved for both alleviating hormone-related symptoms for functional tumors and inhibiting tumor growth. Their anti-proliferative benefit in the refractory setting is debatable due to lack of supportive literature. This systematic review compared efficacy of targeted therapies (Everolimus, Sunitinib, Surufatinib, Lenva...